The approval allows Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark, to distribute these tablets in the US market. Based on IQVIATM sales data covering the 12-month period ending in June 2023, the market for Onglyza® Tablets, 2.5 mg and 5 mg, recorded annual sales of approximately $100.7 million.
